| HOME >> BIOLOGY >> TECHNOLOGY |
Investor Relations (US):
Mahmoud Siddig, Director
Taylor Rafferty
Tel: +1-212-889-4350
Email: pharmatechs@taylor-rafferty.com
Website: http://www.taylor-rafferty.com
Investor Relations (HK):
Ruby Yim, Managing Director
Taylor Rafferty
Tel: +852-3196-3712
Email: pharmatechs@taylor-rafferty.com
Website: http://www.taylor-rafferty.com
Media Contact:
John Dudzinsky, Director
Taylor Rafferty
Tel: +1-212-889-4350
Email: pharmatechs@taylor-rafferty.com
Website: http://www.taylor-rafferty.com
WUXI PHARMATECH (CAYMAN) INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
(in thousands of US Dollars, except ordinary share, ADS and par value data)
March 31, December 31,
2008 2007
Assets:
Current assets:
Cash and cash equivalents 73,728 213,585
Restricted cash 6,382 5,526
Accounts receivable, net 34,426 18,199
Inventories 17,539 13,352
Prepaid expenses and other current assets 15,346 11,215
Total current assets 147,421 261,877
Non-current assets:
Goodwill (Note 1) 124,787 --
Property, plant and equipment, net (Note 1) 115,158 73,634
Intangible assets, net (Note 1)
'/>"/>
| SOURCE WuXi PharmaTech Copyright©2008 PR Newswire. All rights reserved |